Ionis Catches The Eye With New Roche Alliance
Executive Summary
October has been a very good month for Ionis. Following US approval of Tegredi, it has now signed a potentially lucrative deal with existing partner Roche for another antisense drug, this time to tackle advanced dry AMD.
You may also be interested in...
Deal Watch: Bayer Ties Up With Twist On Optimization Of Antibody Discovery
Plus deals involving Advanz/Dimerix, Boehringer Ingelheim/Zeiss Medical Technology, Roche/Ionis, Kriya/Everads and updates from the world of technology transfer.
Vico Therapeutics' RNA Modulators For Neurological Diseases Attract Series A Funding
A Netherlands start-up Vico Therapeutics could start clinical trials in late 2021 with its antisense approach to the treatment of rare neurological diseases, financed by its large Series A.
GSK Opts In On Ionis’ Antisense Candidates For Hep B
The pharma is taking over a pair of Ionis candidates intended to address the underlying cause of HBV, possibly offering a curative therapy. It’s just the second HBV licensing agreement in 2019, after heavier deal flow in recent years.